TY - JOUR
T1 - PSA velocity in conservatively managed BPH
T2 - Can it predict the need for BPH-related invasive therapy?
AU - Mochtar, Chaidir A.
AU - Kiemeney, Lambertus A.L.M.
AU - Pilar Laguna, M.
AU - Debruyne, Frans M.J.
AU - De La Rosette, Jean J.M.C.H.
PY - 2006/9/13
Y1 - 2006/9/13
N2 - OBJECTIVE. To study the value of PSA velocity (PSAV) to predict benign prostatic hyperplasia (BPH) progression in patients managed with α1-blockers or watchful waiting (WW). METHODS. Nine hundred and forty two BPH patients treated with α1-blocker or WW were reviewed. PSAV was defined as: (PSAt-PSAb)/(t/12); where PSAt = PSA at time of follow-up (t, in months), PSAb = PSA at baseline. PSAt was taken from the 1 year follow-up visit or, if not present, from the next available visit with a maximum of 24 months. RESULTS. Five hundred and ninety five patients (234 α1-blocker, 361 WW) were included in the analyses. PSAV range was -5.24 to 43.06 ng/ml/year in α1-blocker patients and -6.11 to 19.55 ng/ml/year in WW patients (median: 0.01 ng/ml/year). PSAV was stratified into tertiles (Stable/Decrease/Increase). There were no significant differences in retreatment-free survival and the risk of BPH-related invasive therapy between the tertiles in both treatment groups. CONCLUSIONS. PSAV did not predict BPH progression in either α1-blocker treated patients or WW group.
AB - OBJECTIVE. To study the value of PSA velocity (PSAV) to predict benign prostatic hyperplasia (BPH) progression in patients managed with α1-blockers or watchful waiting (WW). METHODS. Nine hundred and forty two BPH patients treated with α1-blocker or WW were reviewed. PSAV was defined as: (PSAt-PSAb)/(t/12); where PSAt = PSA at time of follow-up (t, in months), PSAb = PSA at baseline. PSAt was taken from the 1 year follow-up visit or, if not present, from the next available visit with a maximum of 24 months. RESULTS. Five hundred and ninety five patients (234 α1-blocker, 361 WW) were included in the analyses. PSAV range was -5.24 to 43.06 ng/ml/year in α1-blocker patients and -6.11 to 19.55 ng/ml/year in WW patients (median: 0.01 ng/ml/year). PSAV was stratified into tertiles (Stable/Decrease/Increase). There were no significant differences in retreatment-free survival and the risk of BPH-related invasive therapy between the tertiles in both treatment groups. CONCLUSIONS. PSAV did not predict BPH progression in either α1-blocker treated patients or WW group.
KW - Adrenergic alpha-blockers
KW - Benign prostatic hyperplasia
KW - Prostate-specific antigen
KW - Treatment outcome
UR - http://www.scopus.com/inward/record.url?scp=33748474819&partnerID=8YFLogxK
U2 - 10.1002/pros.20436
DO - 10.1002/pros.20436
M3 - Review article
C2 - 16741919
AN - SCOPUS:33748474819
SN - 0270-4137
VL - 66
SP - 1407
EP - 1412
JO - Prostate
JF - Prostate
IS - 13
ER -